Eli Lilly is running a direct head-to-head trial comparing the two drugs (NCT06662383, 800 patients)
Driven by unprecedented demand for medical weight-management therapies and metabolic wellness solutions, brands across the supplement, telehealth, pharmacy, and fitness sectors are actively seeking complementary non-prescription products that support appetite regulation, metabolic balance, and long-term weight maintenance
Cost is only one aspect of accessmany urban consumers already spend comparable amounts on discretionary expenses given any weekend
TRIUMPH-2: obesity with type 2 diabetes
These conditions result in the overproduction of AGEs, accumulation of pro-inflammatory and pro-fibrotic factors, and free fatty acid oxidation
For researchers transitioning from semaglutide or tirzepatide to retatrutide, the dose schedule requires a fresh start